Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Related to this article
CHMP backs teclistamab plus daratumumab for earlier use in relapsed/refractory multiple myeloma following strong MajesTEC-3 results.
Daratumumab Retreatment Displays Activity in Relapsed Myeloma Following Continuous Frontline Therapy
Daratumumab-based retreatment remained active in a broadly inclusive, transplant-ineligible newly diagnosed multiple myeloma population.
An off-the-shelf BCMA-directed CAR T-cell therapy generated a 100% overall response rate and universal MRD negativity in heavily pretreated myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Gains NMPA Approval for MET-Amplified Gastric and GEJ Adenocarcinoma
2
Five Under 5: Top Oncology Videos for the Week of 6/28
3
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
4
FDA Issues CRL to Orviglance for Liver Metastasis Imaging in Patients With Severe Kidney Impairment
5